The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $48 million to Kernal Bio to support the development of more efficient,…
News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
GYNECOLOGICAL CANCER
Prolactin-raising antipsychotics may increase gynecological cancer risk
Women prescribed antipsychotics that raise the levels of prolactin, a hormone that stimulates milk production and regulates reproductive hormones, had double the rate of…
C4 Therapeutics and Pfizer are teaming up to evaluate whether combining C4’s investigational oral therapy cemsidomide with Pfizer’s approved multiple myeloma treatment Elrexfio…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias who may benefit from the…
PANCREATIC CANCER
Utidelone now FDA orphan drug after promising cancer trial results
Biostar Pharma’s experimental therapy utidelone has been granted orphan drug status for pancreatic cancer by the U.S. Food and Drug Administration (FDA). The…
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
GYNECOLOGICAL CANCER
Stenoparib may improve survival in hard-to-treat ovarian cancer: Data
The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
PANCREATIC CANCER
Atebimetinib yields ‘extraordinary’ results in pancreatic cancer trial
An experimental cancer therapy known as atebimetinib is delivering “extraordinary” results for patients with pancreatic cancer. New data from an ongoing Phase 2a clinical…
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
Recent Posts
- The parallel calendars: Living between treatment cycles and ordinary days
- First participant receives GLIX1 in early glioblastoma clinical trial
- World Ovarian Cancer Day campaign spotlights scars seen and unseen
- Gilead completes Arcellx buy, securing myeloma treatment anito-cel
- Why the answer to ‘Should I call the doctor?’ is always yes
